Nicotine replacement therapy sampling — Competitive Intelligence Brief

Nicotine replacement therapy sampling (Nicotine replacement therapy sampling) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nicotinic receptor agonist. Area: Addiction Medicine / Smoking Cessation.

marketed Nicotinic receptor agonist Nicotinic acetylcholine receptors Addiction Medicine / Smoking Cessation Small molecule

Target snapshot

Nicotine replacement therapy sampling (Nicotine replacement therapy sampling) — The University of Hong Kong. Nicotine replacement therapy delivers nicotine through non-combustible routes to satisfy nicotine dependence and reduce withdrawal symptoms during smoking cessation.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Nicotine replacement therapy sampling TARGET	Nicotine replacement therapy sampling	The University of Hong Kong	marketed	Nicotinic receptor agonist	Nicotinic acetylcholine receptors
Nicoderm patch first, then Aveva patch	Nicoderm patch first, then Aveva patch	University of Maryland, Baltimore	marketed	Nicotine replacement therapy	Nicotinic acetylcholine receptors
Nicotine gum (C)	Nicotine gum (C)	22nd Century Group, Inc.	marketed	Nicotinic acetylcholine receptor agonist	Nicotinic acetylcholine receptors
nicotine nasal spray	nicotine nasal spray	Heinrich-Heine University, Duesseldorf	marketed	Nicotinic receptor agonist	Nicotinic acetylcholine receptors
Placebo/Galantamine (Reminyl®)	Placebo/Galantamine (Reminyl®)	Ludwig-Maximilians - University of Munich	marketed	Acetylcholinesterase inhibitor	Acetylcholinesterase; nicotinic acetylcholine receptors
Nicoderm C-Q Transdermal Product	Nicoderm C-Q Transdermal Product	University of Miami	marketed	Nicotine replacement therapy (NRT)	Nicotinic acetylcholine receptors
C-11 labeled nicotine	C-11 labeled nicotine	University of Cincinnati	marketed	PET imaging agent / radiotracer	Nicotinic acetylcholine receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nicotinic receptor agonist class)

1. Heinrich-Heine University, Duesseldorf · 1 drug in this class
2. The University of Hong Kong · 1 drug in this class
3. University of Pennsylvania · 1 drug in this class